MedTrace Logo

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

NCT00995787 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-02-26

No results posted yet for this study

Summary

The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.

Conditions

  • Type II Diabetes Mellitus

Interventions

DRUG

AZD1656

Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days

DRUG

Placebo

Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD · AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

  • Marcus Dr. Marcus Hompesch, Dr · Profil Institute for Clinical Research Inc.855 3rd Avenue, Suite 4400Chula VistaCA 91911, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995787 on ClinicalTrials.gov